Human Monoclonal Antibody-Based Therapy in the Treatment of Invasive Candidiasis

Table 2

FICI of AMB in combination with Mycograb, Mycograb C28Y variant, and various protein sources.

C. albicans STRAINS	AGENT	FICI	Outcome	References
ATCC 24433	AMB; MYC C28Y	0.258	Synergy	Louie et al. 2011 [21]
ATCC 90028	AMB; MYC C28Y	0.258	Synergy	Louie et al. 2011 [21]
ATCC 24433; ATCC 90028	AMB; MYC C28Y	0.27 ± 0.18	Synergy	Richie et al. 2012 [22]
ATCC 24433; ATCC 90028	AMB; Mycograb	0.23 ± 0.12	Synergy	Richie et al. 2012 [22]
ATCC 24433; ATCC 90028	AMB; Aurograb	0.14 ± 0.01	Synergy	Richie et al. 2012 [22]
ATCC 24433; ATCC 90028	AMB; Human γ-globulin	0.18 ± 0.07	Synergy	Richie et al. 2012 [22]
ATCC 24433; ATCC 90028	AMB; Human-serum albumin	0.15 ± 0.05	Synergy	Richie et al. 2012 [22]

FICI: fractional inhibitory concentration index.